

## University of Groningen

### **Erratum: Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease**

Dekkers, Claire C J; Wheeler, David C; Sjöström, C David; Stefansson, Bergur V; Cain, Valerie; Heerspink, Hidde J L

*Published in:*  
Nephrology, Dialysis, Transplantation

*DOI:*  
[10.1093/ndt/gfy135](https://doi.org/10.1093/ndt/gfy135)

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*  
Publisher's PDF, also known as Version of record

*Publication date:*  
2018

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Dekkers, C. C. J., Wheeler, D. C., Sjöström, C. D., Stefansson, B. V., Cain, V., & Heerspink, H. J. L. (2018). Erratum: Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease. *Nephrology, Dialysis, Transplantation*, 33(7), 1280. <https://doi.org/10.1093/ndt/gfy135>

#### **Copyright**

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

#### **Take-down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

## Erratum

Claire C.J. Dekkers, David C. Wheeler, C. David Sjöström, Bergur V. Stefansson, Valerie Cain and  
Hiddo J.L. Heerspink

Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease, *Nephrology Dialysis Transplantation*, gfy350, <https://doi.org/10.1093/ndt/gfy350>

In the above article, the n numbers for the least squares mean values (LSM) reported below figure 2A were incorrect. The numbers for Week 102 were repeated under the graph rather than displaying the true LSM values, which were 62 for placebo, 55 for dapagliflozin 5 mg and 85 for dapagliflozin 10 mg. The authors apologise for the error which has been corrected.